Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex r&d expenses
Research and development expenses are spending on new products and technology.
Scilex's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.61M, up 41.3% year over year. For fiscal 2025 it was $20.71M, up 114.8% from the year before. The highest annual figure on record is $20.71M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.71M | +114.8% |
| FY2024 | Dec 31, 2024 | $9.64M | -24.4% |
| FY2023 | Dec 31, 2023 | $12.75M | +40.8% |
| FY2022 | Dec 31, 2022 | $9.05M | -1.6% |
| FY2021 | Dec 31, 2021 | $9.20M | -7.6% |
| FY2020 | Dec 31, 2020 | $9.96M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.34M | -46.1% |
| Q1 FY2026 | Mar 31, 2026 | $3.21M | +30.7% |
| Q4 FY2025 | Dec 31, 2025 | $8.17M | +274.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.90M | +66.0% |
| Q2 FY2025 | Jun 30, 2025 | $6.19M | +208.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.46M | -21.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.18M | -20.3% |
| Q3 FY2024 | Sep 30, 2024 | $2.35M | -42.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.00M | -37.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.11M | +13.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.73M | +5.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.07M | +229.2% |
| Q2 FY2023 | Jun 30, 2023 | $3.20M | +23.8% |
| Q1 FY2023 | Mar 31, 2023 | $2.74M | +4.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.60M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.24M | – |
| Q2 FY2022 | Jun 30, 2022 | $2.59M | – |
| Q1 FY2022 | Mar 31, 2022 | $2.63M | – |